Results 171 to 180 of about 2,784,783 (318)

Annual 12‐Week Dosing Gap of Natalizumab: Clinical Efficacy, Blood Biomarkers, and CSF Cell Composition

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Natalizumab (NTZ) is a highly effective therapy for multiple sclerosis (MS); however, its use is limited by the risk of a rare potentially severe opportunistic brain infection, progressive multifocal leukoencephalopathy (PML). Alternative dosing strategies are evaluated to reduce PML risk while still maintaining efficacy, which ...
Regina Berkovich   +10 more
wiley   +1 more source

Screening for Social Determinants of Health in Patients With Systemic Lupus Erythematosus: A Point‐of‐Care Feasibility Study

open access: yesArthritis Care &Research, EarlyView.
Objective Social determinants of health (SDoH) can impact outcomes but are not routinely screened for in US outpatient rheumatology clinics. This study determined the feasibility of routine point‐of‐care SDoH screening among patients with systemic lupus erythematosus (SLE) and associated barriers and facilitators at the physician, care team, and ...
S. Sam Lim   +11 more
wiley   +1 more source

Agreement of Administrative Pharmacy Dispensing With Self‐Reported Use of Oral Prednisone in US Veterans With Rheumatoid Arthritis

open access: yesArthritis Care &Research, EarlyView.
Objective Administrative claims are used to evaluate oral glucocorticoid use in rheumatoid arthritis (RA), despite limited evidence to support accuracy. We aimed to evaluate the performance of claims‐based algorithms for glucocorticoid use compared to self‐report in an RA population.
Beth I. Wallace   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy